Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions

Core Viewpoint - Esperion has successfully closed a series of financing transactions, including a $150 million senior secured term loan and a new$100 million convertible note, aimed at repaying a significant portion of its existing $265 million convertible debt [1][2]. Financing Transactions - The financing includes a$150 million senior secured term loan led by Athyrium Capital Management and HealthCare Royalty, which will be used to repay $210 million of existing convertible debt [1][3]. - The new$100 million convertible notes will be issued to accredited investors, with proceeds also allocated for operational cash [1][5]. Debt Restructuring - The company has restructured 80% of its existing debt, extending the maturity date by five years or more, which enhances its financial flexibility [2]. - The loan will bear an interest rate of 9.75% if paid in cash and 11.75% if paid in-kind [3]. Investment Confidence - Athyrium Capital Management expressed confidence in Esperion's strategy and its potential for long-term success in developing innovative therapies for cardiovascular diseases [4][18]. Product Information - Esperion's products, NEXLETOL and NEXLIZET, are indicated for reducing the risk of cardiovascular events in patients unable to take statin therapy and for lowering LDL-C levels in adults with primary hyperlipidemia [6].